Your browser doesn't support javascript.
loading
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Woods, Beth S; Sideris, Eleftherios; Sydes, Matthew R; Gannon, Melissa R; Parmar, Mahesh K B; Alzouebi, Mymoona; Attard, Gerhardt; Birtle, Alison J; Brock, Susannah; Cathomas, Richard; Chakraborti, Prabir R; Cook, Audrey; Cross, William R; Dearnaley, David P; Gale, Joanna; Gibbs, Stephanie; Graham, John D; Hughes, Robert; Jones, Rob J; Laing, Robert; Mason, Malcolm D; Matheson, David; McLaren, Duncan B; Millman, Robin; O'Sullivan, Joe M; Parikh, Omi; Parker, Christopher C; Peedell, Clive; Protheroe, Andrew; Ritchie, Alastair W S; Robinson, Angus; Russell, J Martin; Simms, Matthew S; Srihari, Narayanan N; Srinivasan, Rajaguru; Staffurth, John N; Sundar, Santhanam; Thalmann, George N; Tolan, Shaun; Tran, Anna T H; Tsang, David; Wagstaff, John; James, Nicholas D; Sculpher, Mark J.
Affiliation
  • Woods BS; Centre for Health Economics, University of York, York, UK. Electronic address: beth.woods@york.ac.uk.
  • Sideris E; Centre for Health Economics, University of York, York, UK.
  • Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Gannon MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • Alzouebi M; Weston Park Hospital, Sheffield, UK.
  • Attard G; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Birtle AJ; Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
  • Brock S; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK.
  • Cathomas R; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; Kantonsspital Graubünden, Chur, Switzerland.
  • Chakraborti PR; Royal Derby Hospital, Derby, UK.
  • Cook A; Gloucestershire Oncology Centre, Cheltenham, UK.
  • Cross WR; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Dearnaley DP; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
  • Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth, UK.
  • Gibbs S; Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, UK.
  • Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK.
  • Hughes R; Mount Vernon Group, Mount Vernon Hospital, Northwood, UK.
  • Jones RJ; University of Glasgow, UK.
  • Laing R; St Luke's Cancer Centre, Royal Surrey NHS Trust, Guildford, UK.
  • Mason MD; School of Medicine, Cardiff University, Cardiff, UK.
  • Matheson D; University of Wolverhampton, Wolverhampton, UK.
  • McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK.
  • Millman R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
  • O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
  • Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, Burnley, UK.
  • Parker CC; The Royal Marsden NHS Foundation Trust, London, UK.
  • Peedell C; South Tees NHS Foundation Trust, Middlesbrough, UK.
  • Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK.
  • Ritchie AWS; Gloucestershire Royal Hospital Foundation Trust, Gloucester, UK.
  • Robinson A; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, UK.
  • Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; Forth Valley Royal Hospital, Larbert, UK.
  • Simms MS; Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.
  • Srihari NN; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK.
  • Srinivasan R; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
  • Staffurth JN; Velindre Cancer Centre, Cardiff and School of Medicine, Cardiff University, Cardiff, UK.
  • Sundar S; University of Nottingham, Nottingham, UK.
  • Thalmann GN; Department of Urology, University Hospital Bern, Bern, Switzerland.
  • Tolan S; Clatterbridge Cancer Centre, Birkenhead, UK.
  • Tran ATH; The Christie NHS Foundation Trust, Manchester, UK.
  • Tsang D; Southend and Basildon Hospitals, Southend, UK.
  • Wagstaff J; Swansea University College of Medicine, Swansea, UK.
  • James ND; Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
  • Sculpher MJ; Centre for Health Economics, University of York, York, UK.
Eur Urol Oncol ; 1(6): 449-458, 2018 12.
Article in En | MEDLINE | ID: mdl-31158087
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur Urol Oncol Year: 2018 Document type: Article Country of publication: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Cost-Benefit Analysis Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Aged / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur Urol Oncol Year: 2018 Document type: Article Country of publication: Países Bajos